NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

CARY, N.C. (July 21, 2017) — Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.'s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Admi... (Source: McKesson News)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2vtk02W
via IFTTT